• Fellowship: Hematology and Medical Oncology, University of Cincinnati / Medical Center.
• Residency: Internal Medicine, Medical College of Ohio (now the University of Toledo Health Science-Pathology).
• Medical Degree: Nilratan Sircar Medical College / University of Calcutta, India
• Board Certifications: Dr. Ghose is board certified in both Hematology and Medical Oncology by the American Board of Internal Medicine.
Dr. Abhimanyu Ghose, a board-certified hematologist and medical oncologist, is dedicated to translating research into exceptional patient care. His F.A.C.P. (Fellow of the American College of Physicians) designation signifies his commitment to professional excellence and rigorous standards in internal medicine, a foundation for his expertise in oncology.
Research highlights
• Dr. Ghose has co-authored over 30 peer-reviewed articles in oncology, demonstrating a strong track record of scholarly contributions.
• Conference Presentations: He actively shares his research findings at national and international conferences, including the American College of Physicians (ACP), the American Society of Clinical Oncology (ASCO), the Society of General Internal Medicine (SGIM), and the American Society of Hematology (ASH).
• Clinical Trial Involvement: Dr. Ghose has participated and has been the investigator in multiple phase 3 clinical trials, showcasing his dedication to evaluating new and improved treatment options for cancer patients.
• Specific Areas of Expertise: While Dr. Ghose treats a broad spectrum of cancers, his research experience includes areas such as Diffuse Large B cell lymphoma, pancreato-biliary neoplasms, lung, genito-urinary neoplasms. Many of his clinical trial work has been in the field of immunotherapy in lung and genito-urinary cancers.
Example Publications:
One of his co-authored publications, “Advanced biliary tract cancer: clinical outcomes with ABC-02 regimen and analysis of prognostic factors in a tertiary care center in the United States,” was published in the Journal of Gastrointestinal Oncology.
Another co-authored study, “The JAVELIN Medley VEGF: phase 2 study of avelumab + axitinib in patients with previously treated non-small cell lung cancer (NSCLC) or treatment naive, cisplatin-ineligible urothelial cancer” was published in Journal for Immunotherapy of Cancer.